Clinical Trials Logo

Clinical Trial Summary

Postoperative delirium (POD) is the most common complications (~50-60%) in elderly and major challenges to our rapidly growing aging population. Growing evidence suggests a possible role for neuroinflammation in the development of delirium, which is facilitated by a transient increase in blood-brain barrier (BBB) permeability. Lidocaine and dexmedetomidine, commonly used anesthetic adjuncts, have anti-inflammatory properties. Both drugs are reported to have modulatory effect on the intergrity of BBB and associated with a beneficial effect on postoperative neurocognitive dysfunction. In this regard, The investigators aimed to prospectively compare the modulatory effect of the intraoperative administration of dexmedetomidine or lidocaine with a sham control group (normal saline solution) on surgery-induced BBB disruption.


Clinical Trial Description

Postoperative delirium (POD) negatively affects cognitive domains including memory, attention, and concentration after surgery. The incidence of POD in high-risk populations, such as aged, patients in intensive care units (ICU) and with previous cognitive impairment, the incidence of POD is as high as 50 to 60%. POD is associated with increased morbidity, mortality, and health-care costs. The 1-year survival probability is reduced by approximately 10% for each additional day of POD. Additionally, it is closely related to long-lasting postoperative cognitive dysfunction. Surgical trauma activates the innate immune system and central nervous system (CNS) is influenced by surgical trauma by inflammatory mediators rapidly reaching the brain, which is facilitated by a transient increase in blood-brain barrier (BBB) permeability. Recent neuroimaging studies demonstrated BBB dysfunction in patients with delirium after cardiac surgery. The biomakers indicative of BBB breakdown were recently associated with the onset and intensity of delirium. These findings imply that the BBB could serve as a pivotal interface in regulating neuroinflammation and cognitive deterioration following surgical procedures. Dexmedetomidine and lidocaine are increasingly used as part of a multimodal intraoperative anesthetic adjunct in a variety of surgical procedures. Dexmedetomidine, as a highly selective central presynaptic α2-adrenergic agonist, has sedative, sympatholytic and anti-inflammatory effects. Perioperative dexmedetomidine administration reduced delirium incidence by up to 50% and duration by 0.7 days in surgical populations. Lidocaine, an amide local anesthetic and class-1 antiarrhythmic agent, also has anti-inflammatory and opiate-sparing effects, accelerating gastrointestinal recovery and reducing hospital length of stay. In addition, previous clinical researches have suggested a beneficial effect of perioperative systemic lidocaine on postoperative neurocognitive dysfunction. Although both drugs alleviate surgery-induced systemic inflammation and animal models have indicated a potential protective effect of these agents against surgery-induced disruption of the BBB, few studies have examined the role of these different anesthetics in the interplay between peripheral and central inflammation in human subjects. In this regard, this study aimed to prospectively compare the modulatory effect of the intraoperative administration of dexmedetomidine or lidocaine with a sham control group (normal saline solution) on surgery-induced BBB disruption in a randomized, placebo-controlled, double-blind, triple-parallel clinical trial. The primary outcome measure was "cerebrospinal-plasma albumin ratio (CPAR)", which is a gold standard measure for BBB permeability, presenting in vivo evidence for the physical breakdown of the blood-CSF barrier in human. The investigators hyptothesized that the use of intraoperative continuous infusion of dexmedetomidine or lidocaine would be statistically superior to placebo control in preserving BBB integrity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06090955
Study type Interventional
Source Samsung Medical Center
Contact jeayoun kim
Phone +821039268786
Email kimjy0705@naver.com
Status Recruiting
Phase N/A
Start date October 25, 2023
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06392308 - The Impact of Smoking on the Prognosis of Elderly Surgical Patients
Completed NCT06302517 - Bis Monitoring Effect on Delirium Occurrence and Nursing Quality Improvement Recovering From General Anesthesia N/A
Recruiting NCT06052397 - Sleep and Circadian Rhythm Biomarkers of Postoperative Delirium
Not yet recruiting NCT06107517 - DREAMS-OT Trial: Delirium Reduction Through Early Activation in Motivating and Sleep Promoting Routines: A Randomized Controlled Trial of Occupational Therapy for ICU Patients After Coronary Artery Bypass Graft (CABG) Surgery N/A
Completed NCT04563858 - Polish Validation 4AT Tool
Completed NCT06268119 - Effectiveness of Delirium Care Protocol After Cardiac Surgery N/A
Not yet recruiting NCT06268080 - Depth of Anesthesia on Postoperative Delirium and Cognitive After Surgery N/A
Recruiting NCT06360549 - Effect of Percutaneous Acupoint Electrical Stimulation on Delirium N/A
Completed NCT06187389 - Validation and Reliability of the Turkish 4AT Scale for Post-Anesthesia Awakening Delirium
Recruiting NCT01283412 - Dexmedetomidine on Postoperative Delirium and Quality of Recovery in Geriatric Patients Phase 3
Recruiting NCT06318364 - Postoperative Delirium in the Post-anesthesia Care Unit
Recruiting NCT06318351 - Transcutaneous Acupoint Electrical Stimulation and Postoperative Delirium Delirium
Completed NCT01032161 - Perioperative Risk Factors for Postoperative Delirium in Children N/A
Recruiting NCT05942183 - The Relationship Between Optic Nerve Sheath Diameter and Postoperative Delirium in Open Heart Surgery
Not yet recruiting NCT06361238 - Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery Phase 3
Not yet recruiting NCT06346990 - The Effect of Listening to Holy Quran Recital on the Incidence of Delirium Post-CABG N/A